Fredun Pharmaceuticals Q2 profit rises 93% as sales climb 85%

Fredun Pharmaceuticals Limited reported standalone profit after tax of Rs 18.83 crore for the quarter ended September 30, 2026, up 93% from Rs 9.73 crore a year earlier, as net sales rose 85% to Rs 265.85 crore. Profit before tax increased to Rs 29.90 crore from Rs 13.01 crore in the comparable quarter.

How did Fredun Pharmaceuticals perform in the September quarter?

Fredun Pharmaceuticals nearly doubled standalone quarterly profit in the quarter ended September 30, 2026, with profit after tax increasing by Rs 9.10 crore from Rs 9.73 crore in the September 2025 quarter to Rs 18.83 crore. Net sales increased by Rs 122.26 crore over the same comparison, reaching Rs 265.85 crore from Rs 143.59 crore.

Total income from operations rose to Rs 267.64 crore from Rs 145.29 crore, an increase of 84%. Other operating income was Rs 1.78 crore in the September 2026 quarter, compared with Rs 1.71 crore a year earlier, meaning net sales accounted for most of the Rs 122.35 crore increase in total operating income.

Sequentially, profit after tax rose from Rs 13.17 crore in the quarter ended June 30, 2026, to Rs 18.83 crore in the September quarter. Net sales increased from Rs 227.76 crore in the preceding quarter, while profit before tax rose from Rs 20.59 crore, showing higher reported revenue and pre-tax profit in the second quarter.

What changed in Fredun Pharmaceuticals' costs and profitability?

Fredun Pharmaceuticals reported total expenses of Rs 237.73 crore in the September 2026 quarter, compared with Rs 132.29 crore a year earlier. The Rs 105.45 crore increase in expenses was lower than the Rs 122.35 crore growth in total operating income, and profit before tax consequently rose by Rs 16.89 crore to Rs 29.90 crore.

Cost of material consumed was the largest expense at Rs 239.81 crore, up from Rs 99.26 crore in the September 2025 quarter. The results also recorded a Rs 47.74 crore reduction in inventories of finished goods, work in progress and stock in trade, compared with an expense of Rs 4.41 crore under that line a year earlier; this reduced total reported expenses in the latest quarter.

Other expenses rose to Rs 17.96 crore from Rs 6.14 crore, while employee benefit expenses increased to Rs 9.11 crore from Rs 8.30 crore. Finance costs were Rs 8.78 crore against Rs 7.73 crore, manufacturing and service costs were Rs 4.49 crore against Rs 3.66 crore, and depreciation and amortisation increased to Rs 3.92 crore from Rs 1.60 crore.

Tax expense was Rs 11.08 crore in the September 2026 quarter, compared with Rs 3.27 crore in the prior-year period. Fredun Pharmaceuticals reported no exceptional or prior-period items, no discontinued operations and no other comprehensive income for the quarter, leaving total comprehensive income at Rs 18.83 crore, equal to reported profit after tax.

What do Fredun Pharmaceuticals' half-year results show?

Fredun Pharmaceuticals reported standalone profit after tax of Rs 31.99 crore for the half year ended September 30, 2026, compared with Rs 16.50 crore for the half year ended September 30, 2025. Net sales increased by Rs 230.62 crore to Rs 493.61 crore from Rs 262.99 crore, an 88% year-on-year rise.

Total income from operations for the six months was Rs 495.88 crore, compared with Rs 265.15 crore a year earlier. Profit before tax increased to Rs 50.49 crore from Rs 22.05 crore, while tax expense rose to Rs 18.50 crore from Rs 5.55 crore.

Half-year finance costs increased to Rs 17.39 crore from Rs 14.26 crore, while employee benefit expenses were Rs 16.23 crore compared with Rs 15.93 crore. Basic earnings per share, or EPS, were Rs 19.05 for the half year, compared with Rs 11.65 for the corresponding period after retrospective adjustment for the July 2026 bonus issue.

What were Fredun Pharmaceuticals' capital, audit and listing disclosures?

Fredun Pharmaceuticals reported quarterly basic EPS of Rs 11.21 for the quarter ended September 30, 2026, compared with Rs 6.87 for the September 2025 quarter. The company said EPS for all comparative periods was retrospectively adjusted under Indian Accounting Standard 33 following a bonus-share allotment on July 16, 2026.

On July 16, 2026, Fredun Pharmaceuticals allotted 1,10,25,380 fully paid-up bonus equity shares with a face value of Rs 10 each, in a ratio of two shares for every one share held. During the half year, it also allotted 1,60,533 equity shares after conversion of an equal number of warrants, and paid-up equity share capital stood at Rs 16.90 crore on September 30, 2026, compared with Rs 14.17 crore a year earlier.

The statutory auditors, Rakesh Nisar & Co, issued an unmodified conclusion on their limited review of the unaudited standalone results approved on November 5, 2026. Fredun Pharmaceuticals said it operates in one segment, pharmaceutical and healthcare, and therefore did not provide segment-level revenue or profit data.

The board also approved a proposal to apply to the National Stock Exchange of India Limited for listing and trading of Fredun Pharmaceuticals' equity shares. The application remains subject to applicable laws, regulations and necessary approvals, according to the November 5, 2026 board-meeting outcome.

Conclusion

Fredun Pharmaceuticals' September-quarter results showed profit after tax increasing 93% to Rs 18.83 crore while net sales grew 85% to Rs 265.85 crore. Over the half year ended September 30, 2026, net sales rose 88% to Rs 493.61 crore and profit after tax increased 94% to Rs 31.99 crore.

The next disclosed corporate development is the proposed application for NSE listing and trading approval. Readers can also watch future results for the effect of the July 16, 2026 bonus allotment of 1,10,25,380 shares and the half-year conversion of 1,60,533 warrants into equity shares.